Skip to main content
Top
Published in: Journal of Translational Medicine 1/2022

Open Access 01-12-2022 | NSCLC | Research

LINC00665 knockdown confers sensitivity in irradiated non-small cell lung cancer cells through the miR-582-5p/UCHL3/AhR axis

Authors: Li-Ming Xu, Ya-Jing Yuan, Hao Yu, Shuai Wang, Ping Wang

Published in: Journal of Translational Medicine | Issue 1/2022

Login to get access

Abstract

Background

The resistance to radiotherapy remains a major obstacle that limits the efficacy of radiotherapy in non-small cell lung cancer (NSCLC). This study aims to illustrate the molecular mechanism underlying the role of LINC00665 in the radiosensitivity of NSCLC, which involves ubiquitin C-terminal hydrolase L3 (UCHL3).

Methods and results

The expression of UCHL3 was determined in clinical tissue samples collected from NSCLC patients and NSCLC cell lines. We found that UCHL3 overexpression occurred in both NSCLC tissues and cells, associated with poor prognosis in NSCLC patients. Mechanistically, UCHL3 stabilized aryl hydrocarbon receptor (AhR) protein through deubiquitination, thereby promoting PD-L1 expression. UCHL3 reduced the radiosensitivity of NSCLC cells by stabilizing AhR protein. Upstream microRNAs (miRNAs) and lncRNAs of UCHL3 were predicted by microarray profiling and validated by functional experiments. LINC00665 functioned as a sponge of miR-582-5p and thus up-regulated the expression of the miR-582-5p target UCHL3. Gain- and loss- of function assays were performed to assess the effects of LINC00665, UCHL3 and miR-582-5p on the in vitro cell malignant behaviors and immune escape as well as on the in vivo tumor growth. Silencing LINC00665 or overexpressing miR-582-5p enhanced the sensitivity of NSCLC cells to radiotherapy. LINC00665 augmented the immune escape of NSCLC cells in vitro and in vivo through stabilizing AhR protein via the miR-582-5p/UCHL3 axis.

Conclusions

Overall, LINC00665 reduced the radiosensitivity of NSCLC cells via stabilization of AhR through the miR-582-5p/UCHL3 axis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.PubMedCrossRef Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.PubMedCrossRef
2.
go back to reference Majeed U, Manochakian R, Zhao Y, Lou Y. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J Hematol Oncol. 2021;14:108.PubMedPubMedCentralCrossRef Majeed U, Manochakian R, Zhao Y, Lou Y. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J Hematol Oncol. 2021;14:108.PubMedPubMedCentralCrossRef
3.
go back to reference Harrington KJ, Billingham LJ, Brunner TB, Burnet NG, Chan CS, Hoskin P, et al. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer. 2011;105:628–39.PubMedPubMedCentralCrossRef Harrington KJ, Billingham LJ, Brunner TB, Burnet NG, Chan CS, Hoskin P, et al. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer. 2011;105:628–39.PubMedPubMedCentralCrossRef
4.
go back to reference Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050–9.PubMedCrossRef Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050–9.PubMedCrossRef
5.
go back to reference Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013;38:729–41.PubMedCrossRef Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013;38:729–41.PubMedCrossRef
6.
go back to reference Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15:409–25.PubMedPubMedCentralCrossRef Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15:409–25.PubMedPubMedCentralCrossRef
7.
go back to reference Gong X, Li X, Jiang T, Xie H, Zhu Z, Zhou F, et al. Combined radiotherapy and anti-PD-L1 antibody synergistically enhances antitumor effect in non-small cell lung cancer. J Thorac Oncol. 2017;12:1085–97.PubMedCrossRef Gong X, Li X, Jiang T, Xie H, Zhu Z, Zhou F, et al. Combined radiotherapy and anti-PD-L1 antibody synergistically enhances antitumor effect in non-small cell lung cancer. J Thorac Oncol. 2017;12:1085–97.PubMedCrossRef
8.
go back to reference Mevissen TET, Komander D. Mechanisms of deubiquitinase specificity and regulation. Annu Rev Biochem. 2017;86:159–92.PubMedCrossRef Mevissen TET, Komander D. Mechanisms of deubiquitinase specificity and regulation. Annu Rev Biochem. 2017;86:159–92.PubMedCrossRef
9.
go back to reference Fang Y, Fu D, Shen XZ. The potential role of ubiquitin c-terminal hydrolases in oncogenesis. Biochim Biophys Acta. 2010;1806:1–6.PubMed Fang Y, Fu D, Shen XZ. The potential role of ubiquitin c-terminal hydrolases in oncogenesis. Biochim Biophys Acta. 2010;1806:1–6.PubMed
10.
go back to reference Fukuda T, Tsuruga T, Kuroda T, Nishikawa H, Ohta T. Functional link between BRCA1 and BAP1 through Histone H2A, heterochromatin and DNA damage response. Curr Cancer Drug Targets. 2016;16:101–9.PubMedCrossRef Fukuda T, Tsuruga T, Kuroda T, Nishikawa H, Ohta T. Functional link between BRCA1 and BAP1 through Histone H2A, heterochromatin and DNA damage response. Curr Cancer Drug Targets. 2016;16:101–9.PubMedCrossRef
11.
go back to reference Ouyang L, Yan B, Liu Y, Mao C, Wang M, Liu N, et al. The deubiquitylase UCHL3 maintains cancer stem-like properties by stabilizing the aryl hydrocarbon receptor. Signal Transduct Target Ther. 2020;5:78.PubMedPubMedCentralCrossRef Ouyang L, Yan B, Liu Y, Mao C, Wang M, Liu N, et al. The deubiquitylase UCHL3 maintains cancer stem-like properties by stabilizing the aryl hydrocarbon receptor. Signal Transduct Target Ther. 2020;5:78.PubMedPubMedCentralCrossRef
12.
go back to reference Campesato LF, Budhu S, Tchaicha J, Weng CH, Gigoux M, Cohen IJ, et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nat Commun. 2020;11:4011.PubMedPubMedCentralCrossRef Campesato LF, Budhu S, Tchaicha J, Weng CH, Gigoux M, Cohen IJ, et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nat Commun. 2020;11:4011.PubMedPubMedCentralCrossRef
13.
go back to reference Wang GZ, Zhang L, Zhao XC, Gao SH, Qu LW, Yu H, et al. The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. Nat Commun. 2019;10:1125.PubMedPubMedCentralCrossRef Wang GZ, Zhang L, Zhao XC, Gao SH, Qu LW, Yu H, et al. The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. Nat Commun. 2019;10:1125.PubMedPubMedCentralCrossRef
15.
go back to reference Wei W, Zhao X, Liu J, Zhang Z. Downregulation of LINC00665 suppresses the progression of lung adenocarcinoma via regulating miR-181c-5p/ZIC2 axis. Aging. 2021;13:17499–515 ((Albany NY)).PubMedPubMedCentralCrossRef Wei W, Zhao X, Liu J, Zhang Z. Downregulation of LINC00665 suppresses the progression of lung adenocarcinoma via regulating miR-181c-5p/ZIC2 axis. Aging. 2021;13:17499–515 ((Albany NY)).PubMedPubMedCentralCrossRef
16.
go back to reference Huang Y, Zhong L, Nie K, Li L, Song S, Liu F, et al. Identification of LINC00665-miR-let-7b-CCNA2 competing endogenous RNA network associated with prognosis of lung adenocarcinoma. Sci Rep. 2021;11:4434.PubMedPubMedCentralCrossRef Huang Y, Zhong L, Nie K, Li L, Song S, Liu F, et al. Identification of LINC00665-miR-let-7b-CCNA2 competing endogenous RNA network associated with prognosis of lung adenocarcinoma. Sci Rep. 2021;11:4434.PubMedPubMedCentralCrossRef
17.
go back to reference Wang H, Wang L, Zhang S, Xu Z, Zhang G. Downregulation of LINC00665 confers decreased cell proliferation and invasion via the miR-138-5p/E2F3 signaling pathway in NSCLC. Biomed Pharmacother. 2020;127: 110214.PubMedCrossRef Wang H, Wang L, Zhang S, Xu Z, Zhang G. Downregulation of LINC00665 confers decreased cell proliferation and invasion via the miR-138-5p/E2F3 signaling pathway in NSCLC. Biomed Pharmacother. 2020;127: 110214.PubMedCrossRef
18.
go back to reference Zhu BVM, Finch-Edmondson M, Lee Y, Wan Y, Sudol M, et al. miR-582-5p Is a tumor suppressor microRNA Targeting the Hippo-YAP/TAZ signaling pathway in non-small cell lung cancer. Cancers. 2021;13(4):756.PubMedPubMedCentralCrossRef Zhu BVM, Finch-Edmondson M, Lee Y, Wan Y, Sudol M, et al. miR-582-5p Is a tumor suppressor microRNA Targeting the Hippo-YAP/TAZ signaling pathway in non-small cell lung cancer. Cancers. 2021;13(4):756.PubMedPubMedCentralCrossRef
19.
go back to reference De Bruycker S, Vangestel C, Van den Wyngaert T, Pauwels P, Wyffels L, Staelens S, et al. (18)F-Flortanidazole hypoxia PET holds promise as a prognostic and predictive imaging biomarker in a lung cancer xenograft model treated with metformin and radiotherapy. J Nucl Med. 2019;60:34–40.PubMedCrossRef De Bruycker S, Vangestel C, Van den Wyngaert T, Pauwels P, Wyffels L, Staelens S, et al. (18)F-Flortanidazole hypoxia PET holds promise as a prognostic and predictive imaging biomarker in a lung cancer xenograft model treated with metformin and radiotherapy. J Nucl Med. 2019;60:34–40.PubMedCrossRef
21.
go back to reference Yang R, Liu N, Chen L, Jiang Y, Shi Y, Mao C, et al. GIAT4RA functions as a tumor suppressor in non-small cell lung cancer by counteracting Uchl3-mediated deubiquitination of LSH. Oncogene. 2019;38:7133–45.PubMedCrossRef Yang R, Liu N, Chen L, Jiang Y, Shi Y, Mao C, et al. GIAT4RA functions as a tumor suppressor in non-small cell lung cancer by counteracting Uchl3-mediated deubiquitination of LSH. Oncogene. 2019;38:7133–45.PubMedCrossRef
22.
go back to reference Li G, Jin X, Zheng J, Jiang N, Shi W. UCH-L3 promotes non-small cell lung cancer proliferation via accelerating cell cycle and inhibiting cell apoptosis. Biotechnol Appl Biochem. 2021;68:165–72.PubMedCrossRef Li G, Jin X, Zheng J, Jiang N, Shi W. UCH-L3 promotes non-small cell lung cancer proliferation via accelerating cell cycle and inhibiting cell apoptosis. Biotechnol Appl Biochem. 2021;68:165–72.PubMedCrossRef
23.
go back to reference Shen M, Xie S, Rowicki M, Michel S, Wei Y, Hang X, et al. Therapeutic targeting of metadherin suppresses colorectal and lung cancer progression and metastasis. Cancer Res. 2021;81:1014–25.PubMedCrossRef Shen M, Xie S, Rowicki M, Michel S, Wei Y, Hang X, et al. Therapeutic targeting of metadherin suppresses colorectal and lung cancer progression and metastasis. Cancer Res. 2021;81:1014–25.PubMedCrossRef
24.
go back to reference Malayaperumal S, Sriramulu S, Jothimani G, Banerjee A, Pathak S. A review of AEG-1 oncogene regulating microrna expression in colon cancer progression. Endocr Metab Immune Disord Drug Targets. 2021;21:27–34.PubMedCrossRef Malayaperumal S, Sriramulu S, Jothimani G, Banerjee A, Pathak S. A review of AEG-1 oncogene regulating microrna expression in colon cancer progression. Endocr Metab Immune Disord Drug Targets. 2021;21:27–34.PubMedCrossRef
25.
go back to reference Abdel Ghafar MT, Elkhouly RA, Elnaggar MH, Mabrouk MM, Darwish SA, Younis RL, et al. Utility of serum neuropilin-1 and angiopoietin-2 as markers of hepatocellular carcinoma. J Investig Med. 2021;69:1222–9.PubMedCrossRef Abdel Ghafar MT, Elkhouly RA, Elnaggar MH, Mabrouk MM, Darwish SA, Younis RL, et al. Utility of serum neuropilin-1 and angiopoietin-2 as markers of hepatocellular carcinoma. J Investig Med. 2021;69:1222–9.PubMedCrossRef
26.
go back to reference Yan B, Liu S, Shi Y, Liu N, Chen L, Wang X, et al. Activation of AhR with nuclear IKKalpha regulates cancer stem-like properties in the occurrence of radioresistance. Cell Death Dis. 2018;9:490.PubMedPubMedCentralCrossRef Yan B, Liu S, Shi Y, Liu N, Chen L, Wang X, et al. Activation of AhR with nuclear IKKalpha regulates cancer stem-like properties in the occurrence of radioresistance. Cell Death Dis. 2018;9:490.PubMedPubMedCentralCrossRef
27.
go back to reference Mao C, Wang M, Qian B, Ouyang L, Shi Y, Liu N, et al. Aryl hydrocarbon receptor activated by benzo (a) pyrene promotes SMARCA6 expression in NSCLC. Am J Cancer Res. 2018;8:1214–27.PubMedPubMedCentral Mao C, Wang M, Qian B, Ouyang L, Shi Y, Liu N, et al. Aryl hydrocarbon receptor activated by benzo (a) pyrene promotes SMARCA6 expression in NSCLC. Am J Cancer Res. 2018;8:1214–27.PubMedPubMedCentral
28.
go back to reference Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, et al. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer. 2017;112:200–15.PubMedCrossRef Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, et al. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer. 2017;112:200–15.PubMedCrossRef
29.
go back to reference Liu M, Chen H, Chen X, Xiong J, Song Z. Silencing UCHL3 enhances radio-sensitivity of non-small cell lung cancer cells by inhibiting DNA repair. Aging. 2021;13:14277–88 ((Albany NY)).PubMedPubMedCentralCrossRef Liu M, Chen H, Chen X, Xiong J, Song Z. Silencing UCHL3 enhances radio-sensitivity of non-small cell lung cancer cells by inhibiting DNA repair. Aging. 2021;13:14277–88 ((Albany NY)).PubMedPubMedCentralCrossRef
30.
go back to reference Ji W, Diao YL, Qiu YR, Ge J, Cao XC, Yu Y. LINC00665 promotes breast cancer progression through regulation of the miR-379-5p/LIN28B axis. Cell Death Dis. 2020;11:16.PubMedPubMedCentralCrossRef Ji W, Diao YL, Qiu YR, Ge J, Cao XC, Yu Y. LINC00665 promotes breast cancer progression through regulation of the miR-379-5p/LIN28B axis. Cell Death Dis. 2020;11:16.PubMedPubMedCentralCrossRef
31.
go back to reference Chen W, Yu Z, Huang W, Yang Y, Wang F, Huang H. LncRNA LINC00665 promotes prostate cancer progression via miR-1224-5p/SND1 Axis. Onco Targets Ther. 2020;13:2527–35.PubMedPubMedCentralCrossRef Chen W, Yu Z, Huang W, Yang Y, Wang F, Huang H. LncRNA LINC00665 promotes prostate cancer progression via miR-1224-5p/SND1 Axis. Onco Targets Ther. 2020;13:2527–35.PubMedPubMedCentralCrossRef
32.
go back to reference Qi H, Xiao Z, Wang Y. Long non-coding RNA LINC00665 gastric cancer tumorigenesis by regulation miR-149-3p/RNF2 axis. Onco Targets Ther. 2019;12:6981–90.PubMedPubMedCentralCrossRef Qi H, Xiao Z, Wang Y. Long non-coding RNA LINC00665 gastric cancer tumorigenesis by regulation miR-149-3p/RNF2 axis. Onco Targets Ther. 2019;12:6981–90.PubMedPubMedCentralCrossRef
33.
go back to reference Habib EM, Nosiar NA, Eid MA, Taha AM, Sherief DE, Hassan AE, et al. MiR-150 expression in chronic myeloid leukemia: relation to imatinib response. Lab Med. 2022;53:58–64.PubMedCrossRef Habib EM, Nosiar NA, Eid MA, Taha AM, Sherief DE, Hassan AE, et al. MiR-150 expression in chronic myeloid leukemia: relation to imatinib response. Lab Med. 2022;53:58–64.PubMedCrossRef
34.
go back to reference Liu X, Lu X, Zhen F, Jin S, Yu T, Zhu Q, et al. LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC. Mol Ther Nucleic Acids. 2019;16:155–61.PubMedPubMedCentralCrossRef Liu X, Lu X, Zhen F, Jin S, Yu T, Zhu Q, et al. LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC. Mol Ther Nucleic Acids. 2019;16:155–61.PubMedPubMedCentralCrossRef
35.
go back to reference Yang D, Feng W, Zhuang Y, Liu J, Feng Z, Xu T, et al. Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells. Mol Ther Nucleic Acids. 2021;23:1053–65.PubMedPubMedCentralCrossRef Yang D, Feng W, Zhuang Y, Liu J, Feng Z, Xu T, et al. Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells. Mol Ther Nucleic Acids. 2021;23:1053–65.PubMedPubMedCentralCrossRef
36.
go back to reference Liu J, Liu S, Deng X, Rao J, Huang K, Xu G, et al. MicroRNA-582-5p suppresses non-small cell lung cancer cells growth and invasion via downregulating NOTCH1. PLoS ONE. 2019;14: e0217652.PubMedPubMedCentralCrossRef Liu J, Liu S, Deng X, Rao J, Huang K, Xu G, et al. MicroRNA-582-5p suppresses non-small cell lung cancer cells growth and invasion via downregulating NOTCH1. PLoS ONE. 2019;14: e0217652.PubMedPubMedCentralCrossRef
37.
go back to reference Dittmann KH, Rothmund MC, Paasch A, Mayer C, Fehrenbacher B, Schaller M, et al. The nuclear aryl hydocarbon receptor is involved in regulation of DNA repair and cell survival following treatment with ionizing radiation. Toxicol Lett. 2016;240:122–9.PubMedCrossRef Dittmann KH, Rothmund MC, Paasch A, Mayer C, Fehrenbacher B, Schaller M, et al. The nuclear aryl hydocarbon receptor is involved in regulation of DNA repair and cell survival following treatment with ionizing radiation. Toxicol Lett. 2016;240:122–9.PubMedCrossRef
Metadata
Title
LINC00665 knockdown confers sensitivity in irradiated non-small cell lung cancer cells through the miR-582-5p/UCHL3/AhR axis
Authors
Li-Ming Xu
Ya-Jing Yuan
Hao Yu
Shuai Wang
Ping Wang
Publication date
01-12-2022
Publisher
BioMed Central
Keywords
NSCLC
NSCLC
Published in
Journal of Translational Medicine / Issue 1/2022
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-022-03516-2

Other articles of this Issue 1/2022

Journal of Translational Medicine 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.